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DISCUSSION
Dr. David J. Hamerman (New York), Chairman: Dr. Dziewiatkowski pre-
sented some data on the tumover of hyaluronate and chondroitin sulfate in skin,
and Dr. Sara Schiller from the University of Chicago has kindly consented to dis-
cuss some of these aspects.
Dr. Sara Schiller (Chicago): We don't feel that the decay curves tell us the
entire story about turnover of mucopolysaccharides under the influence of hor-
mones. Recently we determined the concentration of mucopolysaccharides under
various hormonal conditions.
In the alloxan diabetic animal we find lower than normal concentrations of
hyaluronic acid and chondroitin sulfate. Concentrations of hyaluronic acid and
chondroitin sulfate have not been determined, as yet, in animals treated with
adrenal steroids but the turnover of hyaluronic acid and chondroitin sulfate is
slower than normal, and we suspect that the concentration of both substances is
also less than normal.
In the hypothyroid animal the concentration of hyaluronic acid is increased
whereas that of chondroitin sulfate is decreased. When thyroxine is administered
the concentration of both mucopolysaccharides reverts toward normal levels.
In the hypophysectomized animal, we find the same picture as in the hypothyroid
animal: The hyaluronic acid concentration is increased, and the chondroitin sul-
fate concentration is decreased. When growth hormone is administered to these
anmals, the concentration of hyaluronic acid increases markedly. Our normal
values run about 800 micrograms of hyaluronic acid per gram of dry skin. In the
hypothyroid and hypophysectomized animals, they run about 1200 to 1400 micro-
grams of hyaluronic acid, and in the hypophysectomized animal treated with growth
hormone, they run about 2000. Under the influence of growth hormone, the level
of chondroitin sulfate is restored to normal.
When the concentration of both mucopolysaccharides is decreased, as in the
diabetic animal and in the animal treated with adrenal steroids, the defect may
reside in the early stages of biosynthesis, probably at the level of glucose transport
or phosphorylation. In the hypothyroid and the hypophysectomized animal, a defect
higher in the biosynthetic pathyway is anticipated.
It appears that UDPGA and UDP-N-acetyl glucosamine are the precursors for
hyaluronic acid. Jacobson and Davidson have isolated, from the skin of rabbits,
an isomerase that converts UDPGA to UDP iduronic acid, and another isomerase
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that converts UDP-N-acetyl glucosamine to UDP-N-acetyl galactosamine. Both
are dependent on DPN and inhibited by DPNH. It is possible that the increase in
concentration of hyaluronic acid found in the hypothyroid rat is due either to an
increase in DPNH, which inhibits the conversion of the UDGPA to iduronic acid,
or to a defect in activity of both isomerases.
Dr. M. M. Kini (New Haven): I will address this question to Dr. Holtzer. In
your spinal cord or notochord experiments, is the morphologic integrity of the
tissue necessary or does the dialyzed homogenate cause a similar effect on chon-
drogenesis?
Dr. H. Holtzer (Philadelphia): If the notochord is cultured by itself for ap-
proximately 10 hours it loses its tubular configuration. If somites are added to such
a collection of notochord cells, cartilage is not induced. I have not worked with
extracts which simulate the action of the native inducers.
Dr. T. T. Tsaltas (Philadelphia): I wish to refer this question to Dr. Thomas
and Dr. Holtzer. We have been investigating a lipemia produced in adult rabbits
by the intravenous injection of papain. During the study of this lipemia we observed
that some of the animals receiving papain developed some very peculiar lesions in
the aorta. In these lesions the aortic tissue becomes very rich in basophilic
materiaL
Eventually the aortic tissue changes into cartilage and the cardlage then pro-
ceeds to become bone with well formed trabeculae. The center of such bone is
filled with active bone marrow. Even though we are publishing these data (Nature,
December 8, 1962) we have no explanation at present for this peculiar metaplasia
of the aortic tissue.
I wonder whether Dr. Holtzer or Dr. Thomas could offer any explanation for
this phenomenon; whether it has anything to do with the possible mechanism of
the induction of cartilage formation or whether it could be explained on the basis
of the studies that Dr. Holtzer has reported here.
Dr. Lewis Thomas (New York): I am puzzled too.
Dr. Hamerman: This is a very important question, and I would like to extend
it a little further. Dr. Thomas, perhaps you have some thoughts on the relation-
ship of vitamin A to metastatic calcification. If you administer vitamin A to your
rabbits over a period of time, do they develop metastatic calcification, as might be
the case in long continued administration of vitn A to human beings?
Dr. Thomas: We have not seen it. I must confess that we have not done this
for very long periods of time. We would like very much to find out. I am familiar
with the lesions Dr. Tsaltas has in mind. He has shown some sections to me, and
they are quite impressive.
Dr. Hamerman: The question is whether proteolytic enzymes, in degrading the
protein moiety of polysaccharides, are, in effect, accounting for the turnover of
the entire protein polysaccharide moiety, thus influencing calcification. Dr. Schubert,
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do you want to expand on this for a moment? I know I'm taking you somewhat
by surprise but, as someone else said, that is the chairman's prerogative.
Dr. Schubert: Well, we did some experiments a year or two ago that may
have some bearing on this, but I'm not sure I understand them yet. The experi-
ment is something like this:
You take calcium ion and phosphate ion in a buffered solution of pH 7, at
such concentrations that you get a very light precipitate of calcium phosphate as
a control experiment. You get a definite precipitate of calcium phosphate that you
can measure.
Then in a similar situation you dissolve the calcium and the phosphate in a
solution containing the protein polysaccharide compound. You can let such a
solution stand for days and nothing will precipitate. Of course, at first, we thought
it was simply due to the fact that the polyanion would decrease the calcium ion
activity, so that you would get no precipitation, but this is not the case, because if
you add the equivalent amount of chondroitin sulfate alone, not the protein com-
pound but chondroitin sulfate, then you get the precipitation again.
On the other hand, if you take the protein polysaccharide compound and mix
it with the calcium phosphate and let it stand for days, you get no precipitation.
If you add either trypsin or hyaluronidase, you again get immediate precipitation.
This was rather intriguing in connection with the whole process of endochondral
calcification; at the time of disappearance of the protein polysaccharide compound
from the endochondral plate in the area where the big cells are, that is where cal-
cium phosphate seems to be deposited, not as bone but as calcification.
That is a piece of experimental evidence which, as I say, I don't know how to
interpret. We are beginning to think of it in terms of what I talked about a little
this morning-excluded volume-that you may have areas of incipient crystalliza-
tion, but the crystals can't get together.
Question: I would like to come back to the interesting data of Dr. Holtzer.
There is another instance in which cartilage cells lose their roundness, and that is
in the hypophysectomized animal, a hypophysectomized growing rat. They become
flat, I guess, because of the morphologic arrangement. One of the first effects of
injection of growth hormone is that they become round again.
I wonder whether this would not also explain your earlier experiments in the
basement membrane, I think it was, with the somites; that is, we know that nerve
cells in the primitive stage produce polysaccharides in a very simple pattern. The
polypeptide has, in effect, the same effect which growth hormone has at a later
stage.
Dr. Holtzer: At this point I accept anything as possible, for I am quite be-
wildered with the problem of induction on the molecular level. As long as we were
dealing with tissues there was an operational definition of induction. When two
tissues were brought together tissue B did something it would not unless it reacted
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witfi tissue A. As you descend to the molecular level the term as used on the tissue
level gets lost. But once again, almost as a matter of esthetics, I would predict that
the spinal cord and notochord do not act by putting information (i.e., protein or
RNA) into reacting somite cells.
Dr. David S. Howell (Miami): I would like to ask Dr. Dziewiatkowski about
the radioautograms on normal suckling animal epiphyseal cartilage, for S35-sodium
sulfate. The S35 was not incorporated into the bulk of the epiphyseal plates, in
those sections treated with barium hydroxide, but it appeared that there was a sub-
stantial uptake of S85 at the metaphyseal junction. Might not sulfate concentrated
at this site represent more than a simple exchange with extracellular fluid inorganic
sulfate? Could it be released, for example, by a sulfatase from chondroitin sulfate?
Dr. Dominic D. Dziewiatkowski (New York): I believe that the S35 which
one sees in the metaphyses (lower series of autoradiograms in Fig. 6), very shortly
after the administration of the isotope as sulfate, is probably a reflection of the
inorganic sulfate which has been incorporated into the mineral phase of the spicules.
The progressive increase in the concentration of S35 in the metaphyses, sub-
epiphyseally, which one sees after 24 hours, however, is a reflection of chondroitin
sulfate-S35 because of endochondral ossification. In other words, the latter S85-
labeled material was synthesized in the epiphyseal plate and is retained in part as
the cartilage matrix is calcified. Indeed, the strata of S35 in the metaphyses of
estrogenized rats, repeatedly dosed with S35-sulfate (Fig. 11), are in accord with
this suggestion. It was noted that the last dose of S33-sulfate, given 24 hours before
removal of the bones, was reflected in the high concentration of S35 in the epiphy-
seal plate; relative to the latter, the concentration of S35 in the region of the
metaphysis immediately under the epiphyseal plate was low. At some distance from
the plate, however, there was a stratum of S85 in the metaphyses as a result of the
administration of S35-sulfate to the rats a week previously, and at some distance
from this stratum, in the direction of the medullary cavity, there was another
stratum of S35 as a consequence of the administration of S35-sulfate 2 weeks
previously.
Question: In the effect of estradiol S35 uptake of the bone, are there any data
to indicate whether or not this is being mediated through the hypophysis, in par-
ticular, by ACTH, or prothrombin inhibition?
Dr. Dziewiatkowski: Although the uptake of S35-sulfate by cartilage is de-
creased in hypophysectomized rats, it is decreased even further if the rats are given
estradiol benzoate.
Question: Then, this would be a direct effect?
Dr. Dziewiatkowski: Yes, it seems that the effect of estradiol in vivo is not
mediated through the pituitary.
Question: Is there any information or data reflecting the S85 uptake of the
thoracic aorta, and how that is affected by estrogen?
BIOLOGICAL ASPECTS OF MUCOPOLYSACCHARIDE METABOLISM254
Dr. Dziewiatkowski: It is decreased.
Question: By estrogen?
Dr. Dziewiatkowski: Yes, the uptake of S35-sulfate by the thoracic aorta is
also decreased in estrogenized rats. However, although this effect of estradiol on
cartilage is demonstrable within 3 days of treatment, it is necessary to pretreat the
rats for 3 weeks before the effect is seen in the aorta.
Question: Are any of these physiologic doses or have all these been high?
Dr. Dziewiatkowski: In the experiments which were described here the doses
were massive. We used 2 mg once a week and Priest and his coworkers have been
using 0.33 mg daily, 6 days out of the weeks, for a period of 3 or more weeks.
That is not to say that at lower doses qualitatively similar effects cannot be dis-
cerned. They are discernible but are not as striking as at the higher, very large
doses.
Dr. Romano Humberto de Meio (Philadelphia): Dr. Thomas, we understand
that vitamin A, from what we heard, seems to ihibit the deposition of the meta-
chromatic-staining substances and that the same effect is seen from cortisone.
Now, the combined effect seems to be an inhibition by cortisone of the effect of
vitamin A. I wondered how this can be explained.
Dr. Lewis Thomas: I think the fact is that vitamin A is not inhibiting the depo-
sition of the metachromatic material. It brings about its removal, presumably,
by causing the release of enzymes in the tissue and of properties similar to those
of papain. Cortisone blocks this, presumably, by an effect leading to stabilization
of lysosomes. This property of cortisone is quite separate from, and perhaps alt-
gether independent of, the well known and established property of cortisone to
inhibit the synthesis of chondroitin sulfate or chondromucoprotein. They -are quite
separate, and indeed they involve different doses. It takes a large dose of cortisone,
in treating a rabbit, to block the effects of the vitamin A, and a similar dose,
following the papain experiment, to prevent the reconstitution of the cartilage
matrix. But they are, I think, separate events.
Dr. de Meio: Yet I remember, in your slide, the tissue of the animals treated
with the combined vitamin A and cortisone still showed metachromatic staining.
Dr. Thomas: Oh, yes. The degree of metachromasia is that of the normal
animal. These are short term experiments. You treat with cortisone and administer
vitamin A and study the animals for the next 3 or 4 days. This is far too short a
time for cortisone treatment alone to have any discernible effect or cartilage effect.
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